SEC Tracker
Get the app
VSTM · XBRL financial data

Verastem financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (VSTM's year ends in late December)

In millions of dollarsJun 30, 2023Sep 30, 2023Dec 31, 2023Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue———100*0*—21118*1940
Revenue from contracts with customers———100*0*——————
Research and development131423*182521*29252932*3841
Selling, general and administrative779*101211*15212124*2227
General and administrative———————7———9
Operating income (loss)(20)(21)(31)*(18)(37)(32)*(44)(44)(41)(41)*(45)(33)
Interest income122*111*1111*11
Interest expense111*111*0000*00
Other income (expense)(0)(0)(0)*(0)(0)0*(0)(0)(0)(0)*(0)(0)
Income tax expense (benefit)00—000*00*0*—01
Net income (loss)(24)(20)(27)*(8)(24)(65)*(52)(26)(99)(33)*(37)(35)
Earnings per share, basic USD per share(1.37)(0.75)—(0.31)(0.60)—(0.96)(0.39)(1.35)(0.39)*(0.37)(0.35)
Earnings per share, diluted USD per share(1.37)(0.75)—(0.31)(0.60)—(0.96)(0.62)(1.35)—(0.46)(0.35)
Weighted average shares, basic millions of shares1827—2740—54667383*98100
Weighted average shares, diluted millions of shares—27—2740—54747376*99100

Balance sheet

CSV

Fiscal quarters (VSTM's year ends in late December)

In millions of dollarsJun 30, 2023Sep 30, 2023Dec 31, 2023Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents18395788311389118164138205166136
Short-term investments——————————16—
Marketable securities—7159—————————
Inventory———————12222
Prepaid and other current assets797576778898
Total current assets19017414410012195125174154223203176
Property and equipment, net000000000———
Right-of-use asset111111111033
Total assets192176150106126102132196177246228207
Accounts payable5577447810121018
Accrued liabilities141618172226253845545154
Total current liabilities212426303731365060726778
Lease liability, non-current111——10———22
Total liabilities6972716694130164160192189146157
Accumulated deficit(778)(798)(825)(867)(891)(956)(1,008)(1,034)(1,132)(1,165)(1,202)(1,236)
Total stockholders' equity10283571911(29)(32)36(16)578250
Total liabilities and equity192176150106126102132196177246228207
Common shares outstanding (cover page) millions of shares252525404525556267888891

Cash flows

CSV

Fiscal quarters (VSTM's year ends in late December)

In millions of dollarsJun 30, 2023Sep 30, 2023Dec 31, 2023Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(24)(20)(27)*(8)(24)(65)*(52)(26)(99)(33)*(37)(35)
Stock-based compensation1*2*2*2*2*2*23*2*2*23*
Net cash from operating activities(20)*(17)*(30)*(28)*(24)*(25)*(39)(33)*(36)*(30)*(52)(44)*
Purchases of property and equipment———0*0*0*——————
Net cash from investing activities14*(70)*12*29*0*0*———(1)*(16)16*
Proceeds from issuing common stock—(0)*0*——0*3070*0*97*——
Repayments of long-term debt——year only———430*0*(0)*——
Net cash from financing activities91*(1)*(0)*(0)*54*1*6779*18*99*29(2)*
Net change in cash86*(88)*(18)*1*30*(24)*2947*(27)*67*(39)(29)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Verastem13640(44)*90.6M3.1 quarters 10-QJun 30, 2026
Corvus Pharmaceuticals19not reported(15)*84.1M14.0 quarters 10-QJun 30, 2026
DBV Technologies1661.6(52)*314.4M3.2 quarters 10-QSep 30, 2026
Atea Pharmaceuticals77not reported(37)*80.2M5.9 quarters 10-QJun 30, 2026
Annexon199not reported(48)*not reported4.4 quarters 10-QJun 30, 2026
Vanda Pharmaceuticals6270(28)*60.5M1.7 quarters 10-QSep 30, 2026
Tonix Pharmaceuticals Holding17614(42)*17.2M4.2 quarters 10-QJun 30, 2026
Abeona Therapeutics5611(17)*57.2M8.4 quarters 10-QJun 30, 2026
Heron Therapeutics21not reported(2.2)*189.9M19.3 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.